Aulos Bioscience Reports the First Patient Dosing of AU-007 in P-I/II Clinical Trial for the Treatment of Solid Tumors
Shots:
- The 1st patient has been dosed in the P-I/II trial evaluating AU-007 at 4 locations in Australia & 1 site in Huntersville, North Carolina
- The P-I trial consists of 3 dose escalation arms of AU-007 as monotx. or in combination with a single loading dose of recombinant human IL-2 (aldesleukin) or with AU-007 & aldesleukin administered q2w. To define the safety & initial efficacy of AU-007, the P-II portion of the trial will assess the dosing regimen selected from dose escalation for expansion in specified tumor types
- The early clinical data & strong preclinical data showed that AU-007 was found to be safe & well tolerated. AU-007 is a mAb that was computationally created by Biolojic Design to harness the power of IL-2 & kill solid tumors
Ref: Businesswire | Image: Aulos Bioscience
Related News:- Teon Therapeutics Entered into a Clinical Trial Collaboration with Merck to Evaluate TT-816 + Keytruda (pembrolizumab) for Solid Tumors
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
